Comments
Multinational drug-maker GlaxoSmithKline Pharmaceuticals expects to recover some lost ground with the revision of drug prices set to kick-in from this month. The company saw a 42 per cent fall in net profit at ₹96.54 crore for the quarter ended March 31, 2014, compared with ₹169 crore in the corresponding period last year. Total income dipped 8 per cent from ₹713 crore in the quarter ended March 31, 2013, to ₹654 crore in quarter ended March 31, 2014. GSK Pharma’s India chief Hasit Joshipura said that a combination of factors including supply chain constrains in the international and local market had affected both pharmaceutical and vaccine segments.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.